Key facts
- Mission Therapeutics’s last known valuation is $115.2M (Mar 2024).
- It has raised $213.8M; the latest was Later Stage VC ($13.3M) in Oct 2025.
- Notable investors include Innovate UK, Cambridge Enterprise Ventures, Sofinnova Partners, Pfizer Ventures, Revelation Partners — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Mission Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mission Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mission Therapeutics
Operator of a pharmaceutical research and drug discovery company intended to facilitate the development of advanced medical treatments. The company specializes in the research and development of deubiquitylating enzymes and new molecular understandings of human cell biology into drugs that will improve the management of life-threatening diseases, particularly cancer, enabling healthcare professionals to treat unmet diseases.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2011
- Employees
- 14
- Website
- missiontherapeutics.com/
- Ownership
- Privately Held (backing)
Mission Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mission Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mission Therapeutics in its N-PORT filings yet. We sweep new filings monthly.